Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters

Kejian Zhu; Mrowietz, Ulrich
October 2005
Archives of Dermatological Research;Oct2005, Vol. 297 Issue 4, p170
Academic Journal
Fumaric acid esters (FAE) are used for the systemic therapy of psoriasis with high clinical efficacy. Among the potential side effects of FAE therapy, lymphocytopenia is sometimes observed. We have investigated the effect of dimethylfumarate (DMF) and its main metabolite methylhydrogenfumarate (MHF) as well as dexamethasone on superoxide anion generation by human monocytes and neutrophils after stimulation with bacteria ( Staphylococcus aureus and Escherichia coli) and the yeast Candida albicans in addition with zymosan particles and with the tripeptide fMLP. Expression of mannose receptors on monocytes and neutrophils was also analyzed. The results showed that dexamethasone significantly inhibited superoxide anion generation from monocytes in response to bacteria and C. albicans, whereas DMF as well as MHF dose dependently increased the production of superoxide anion in monocytes in response to zymosan, fMLP and bacteria. Dexamethasone, DMF or MHF did not modulate superoxide anion generation of neutrophils. Expression of mannose receptors on monocytes was not regulated by DMF or MHF. Our data provide evidence that DMF and MHF do not alter the production of superoxide anions as an important mechanism of innate defense against microorganisms.


Related Articles

  • Dimethylfumarate Inhibits Angiogenesis In Vitro and In Vivo: A Possible Role for Its Antipsoriatic Effect? García-Caballero, Melissa; Marí-Beffa, Manuel; Medina, Miguel Á; Quesada, Ana R. // Journal of Investigative Dermatology;Jun2011, Vol. 131 Issue 6, p1347 

    The fumaric acid esters (FAEs) have been used for the oral treatment of psoriasis for some 50 years. Given that a persistent and maintained angiogenesis is associated with several cutaneous diseases, including psoriasis, we sought in our study to gain further insight into their mechanism of...

  • Addition of Pentoxifylline Could Reduce the Side Effects of Fumaric Acid Esters in the Treatment of Psoriasis. Friedrich, Markus; Sterry, Wolfram; Ren�r�ckert, Anja Klein; D�cke, Wolf Dietrich; Asadullah, Khusru // Acta Dermato-Venereologica;Nov/Dec2001, Vol. 81 Issue 6, p429 

    Examines the role of pentoxifylline drug on the reduction of side effect of fumaric acid ester (FAE) therapy on patients with Psoriasis. Influence of releasing of tumor necrosis factor-alpha during initial phase of therapy on the adverse effect of FAE; Standard doses of FAE for treatment;...

  • In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. Litjens, Nicolle H. R.; Van Strijen, Elisabeth; Van Gulpen, Co; Mattie, Herman; Van Dissel, Jaap T.; Bing Thio, H.; Nibbering, Peter H. // BMC Pharmacology;2004, Vol. 4, p1 

    Background: Psoriasis is a chronic inflammatory skin disease that can be successfully treated with a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use. These tablets consist of dimethylfumarate (DMF) and salts of monoethylfumarate (MEF) and its main bioactive...

  • Inhibition of Dendritic Cell Differentiation by Fumaric Acid Esters. Zhu, Kejian; Mrowietz, Ulrich // Journal of Investigative Dermatology;Feb2001, Vol. 116 Issue 2, p203 

    Summary Fumaric acid esters have proved to be effective for the systemic treatment of severe psoriasis vulgaris. These compounds have been shown to induce a Th2-like cytokine secretion pattern in T cells and to reduce keratinocyte proliferation in vitro. Dendritic cells seem to be of major...

  • calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate.  // Reactions Weekly;Mar2015, Vol. 1542 Issue 1, p60 

    An abstract of the article "Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre" by K. Steinz and colleagues is presented.

  • Psoriasis: Flaky is only an adjective for piecrusts. Schaefer, Ingrid K. // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS3 

    Editorial. Contemplates on the advances in psoriasis care. Effectiveness of over-the-counter remedies on psoriasis; Challenge for manufacturers to come up with a more effective treatment for proriasis.

  • FDA okays psoriasis indication for a cyclosporine.  // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS25 

    Presents highlights of the Neoral labeling related top psoriasis. Considerations before initiating treatment with the drug; Initial recommended dose for patients with psoriasis; Cautions against the use of Neoral for longer than a year.

  • Patient Education Critical Factor in Successful Tazarotene Use. Moore, Ian J.S. // Dermatology Times;Feb98, Vol. 19 Issue 2, p45 

    States that tazarotene can be used successfully as a first-line treatment in psoriatic patients when they are properly instructed about its use. Factors to consider in prescribing the drug for psoriasis treatment; Common side effects of psoriatic treatment; How to manage the side effects of...

  • Psoriasis solution. Segell, Michael // Cosmopolitan;Sep95, Vol. 219 Issue 3, p94 

    Suggests a treatment for the skin disease called psoriasis. Estimated number of Americans afflicted with psoriasis; Cause of disease; Experimental therapy that may lead to discovery of drug for disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics